Merck (MRK) says WELIREG in combination with lenvatinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, one of the study's dual primary endpoints, for treatment of ccRCC

• Merck & Co said WELIREG in combination with lenvatinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, one of the study's dual primary endpoints, reducing the risk of disease progression or death by 26% in patients with advanced ccRCC whose disease progressed on or after treatment with a PD-1 or PD-L1 inhibitor compared to cabozantinib.
• At the final analysis, overall survival, the study's other dual primary endpoint, did not meet statistical significance for patients who received WELIREG in combination with lenvatinib compared to cabozantinib.

A positive progression-free survival readout against an active comparator in a post-checkpoint population is the standard currency of label-expansion filings in oncology, and regulators in major markets have historically been willing to accept PFS as the basis for approval where overall survival remains immature or confounded by subsequent therapy. The complicating feature here is structural rather than statistical: with dual primary endpoints, a miss on overall survival at final analysis weakens the totality-of-evidence argument and has, in comparable episodes, shaped label breadth, guideline placement and the tone of advisory review even where approval followed. The comparator matters: cabozantinib is an entrenched standard in this setting, so beating it on PFS carries more commercial weight than a placebo-controlled win would. The partnership dimension is also in play, since lenvatinib is a partnered asset and economics on combination regimens are typically shared, diluting single-company capture. The follow-ons that have historically determined how these readouts resolve are the full dataset presentation at a medical meeting, the shape of the survival curves and subgroup consistency, the filing timeline with US and European regulators, and whether the OS trend shows any separation with further follow-up. Trial-readout price reactions of this kind have tended to be sharp on the print and then to retrace or extend based on the quality of the underlying curves rather than the headline hazard ratio alone.